New shot could help lower stubborn high cholesterol
NCT ID NCT07421284
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests an injection called SYH2053 for people with high cholesterol that isn't controlled by standard pills. About 900 adults aged 18-75 will receive either the drug or a placebo, on top of their usual cholesterol medication. The main goal is to see if SYH2053 safely lowers bad cholesterol (LDL-C) levels over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYH2053 injection
What this could lead to
If it works, this could provide a new injectable option to help lower bad cholesterol in people who still have high levels despite standard treatments.
What could go wrong
This is a Phase 3 trial, but it hasn't started yet. The drug may not lower cholesterol enough or could cause side effects. Results may not apply to everyone with high cholesterol.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-FAMILIAL HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliation: Peking University Third Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••